^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Enshuxing (enlonstobart)

    i
    Other names: SG001, SG 001, SYSA1802
    Associations

    News

    Trials
    Company:
    CSPC Pharma, Sumgen Biotech
    Drug class:
    PD1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    4ms
    A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma. (clinicaltrials.gov)
    P1/2, N=129, Not yet recruiting, CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
    Trial completion date • Trial initiation date • Trial primary completion date • Combination therapy • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    cisplatin • paclitaxel • Enshuxing (enlonstobart) • albumin-bound docetaxel (CPO100)
    6ms
    A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma. (clinicaltrials.gov)
    P1/2, N=129, Not yet recruiting, CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
    New P1/2 trial • Combination therapy • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    cisplatin • paclitaxel • Enshuxing (enlonstobart) • albumin-bound docetaxel (CPO100)
    over2years
    Study of the SG001 Injection for Patients With Relapsed or Metastatic Uterine Cervical Cancer (clinicaltrials.gov)
    P2, N=104, Recruiting, CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Not yet recruiting --> Recruiting
    Clinical • Enrollment open
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Enshuxing (enlonstobart)
    over2years
    A Study to Evaluate the Efficacy and Safety of SG001 in Combination With Nab-Paclitaxel in Patients With Advanced Triple-Negative Breast Cancer (TNBC) (clinicaltrials.gov)
    P2, N=79, Recruiting, CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Not yet recruiting --> Recruiting
    Clinical • Enrollment open • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    PD-L1 expression • HER-2 negative • PD-L1 negative • ER negative • PGR negative
    |
    albumin-bound paclitaxel • Enshuxing (enlonstobart)
    over2years
    A Study to Evaluate the Efficacy and Safety of SG001 in Combination With Nab-Paclitaxel in Patients With Advanced Triple-Negative Breast Cancer (TNBC) (clinicaltrials.gov)
    P2, N=79, Not yet recruiting, CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
    Clinical • New P2 trial • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    PD-L1 expression • HER-2 negative • PD-L1 negative • ER negative • PGR negative
    |
    albumin-bound paclitaxel • Enshuxing (enlonstobart)
    over2years
    Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer (clinicaltrials.gov)
    P2, N=66, Not yet recruiting, CSPC Ouyi Pharmaceutical Co., Ltd. | Trial completion date: Aug 2021 --> Aug 2024 | Trial primary completion date: Aug 2021 --> Aug 2023
    Clinical • Trial completion date • Trial primary completion date
    |
    UGT1A1 (UDP glucuronosyltransferase family 1 member A1)
    |
    UGT1A1*1*1
    |
    5-fluorouracil • leucovorin calcium • Enshuxing (enlonstobart) • irinotecan liposomal
    over2years
    Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer (clinicaltrials.gov)
    P2, N=66, Not yet recruiting, CSPC Ouyi Pharmaceutical Co., Ltd.
    Clinical • New P2 trial
    |
    UGT1A1 (UDP glucuronosyltransferase family 1 member A1)
    |
    UGT1A1*1*1
    |
    5-fluorouracil • leucovorin calcium • Enshuxing (enlonstobart) • irinotecan liposomal
    almost3years
    Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC (clinicaltrials.gov)
    P2, N=126, Not yet recruiting, CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    Enshuxing (enlonstobart)
    almost3years
    Study of the SG001 Injection for Patients With Relapsed or Metastatic Uterine Cervical Cancer (clinicaltrials.gov)
    P2, N=104, Not yet recruiting, CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
    Clinical • New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Enshuxing (enlonstobart)
    almost4years
    Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours (clinicaltrials.gov)
    P1, N=192, Recruiting, CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Not yet recruiting --> Recruiting | Trial completion date: Dec 2020 --> Mar 2023 | Trial primary completion date: Oct 2020 --> Sep 2022
    Clinical • Enrollment open • Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • MSI (Microsatellite instability)
    |
    PD-L1 expression • MSI-H/dMMR • ALK mutation
    |
    Enshuxing (enlonstobart)